Complete Genomics, a struggling DNA sequencing company in Silicon Valley, said on Monday that it had agreed to be acquired for USD 117.6 million by BGI-Shenzhen, a Chinese company that operates the world’s largest sequencing operation. The deal will need antitrust clearance, because of two key players in the DNA sequencing business in a highly capital intensive and research intensive industry, as well as clearance from a national security review by the Committee on Foreign Investment in the United States. It also requires approval from certain governmental authorities in China.
Featured News
FTC Warns Patent-Right Acquisitions Cannot Escape Antitrust Review in Amgen Enbrel Case
Aug 24, 2026 by
CPI
nVent Bets $1.75 Billion on Data-Center Power Demand
Aug 24, 2026 by
CPI
Squire Patton Boggs Adds Former FTC Antitrust Lawyer
Aug 24, 2026 by
CPI
Tacoma Sues Fire-Truck Makers in Expanding US Antitrust Fight
Aug 24, 2026 by
CPI
California Breaks Off Paramount Talks Over $110 Billion Warner Bros. Deal
Aug 24, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Antipasto
Aug 24, 2026 by
CPI
“Anti-Monopoly” Antitrust Enforcement: Lessons Learned from the Biden Administration
Aug 24, 2026 by
Diana L. Moss
FTC v. Meta: The Importance of Quantitative Evidence in Antitrust
Aug 24, 2026 by
Dennis Carlton, John A. List, Allan Shampine, Hal Sider & Theresa Sullivan
Competitor Information Exchanges: Reducing Market Uncertainty Is What Matters, Not Level Of Detail
Aug 24, 2026 by
Kasia Czapracka, Assimakis Komninos, James Killick & Nina Frie
When Politics Meets Merger Control: 10 Transatlantic Takeaways
Aug 24, 2026 by
Rachel Brandenburger